Five families, thirty-eight names, and one grant that already counts
Circle Pharma holds 5 patent families: 1 granted and 4 published and pending. Filing began in 2018, with the most recent published filing dated 2025-04-23. The families appear in 2 patent offices: United States and Europe.Patent figures from Google Patents Public Data, reviewed 2026-09-22. Funding: $92.5M Series E, RA Capital Management, Eli Lilly and Pfizer, 2026-09-16.
Circle Pharma closed a $92.5M Series E in September 2026. The first filing in its record is dated July 2018. Between those two dates sits a small, deliberate file: five families, one of them granted. What did eight years of patience actually buy?
The money arrives eight years late
On 16 September 2026, Circle Pharma announced a $92.5M Series E. RA Capital Management, Eli Lilly, Pfizer, The Column Group and Lifeforce Capital are named on it. That is a single loud moment, and it is the moment most readers will remember. It is also the least informative date in the file.
The company was founded in 2012. Its earliest filing carries a first-filing date of 27 July 2018. So the intellectual property record begins eight years before the round that made the company visible, and it begins quietly: one family, then nothing new for five years. Whatever conviction the Series E is priced against was written down long before anyone was asked to price it.
One ribbon is narrow and finished
Five families. One granted. Four published and pending. Twenty per cent conversion, which looks thin until you notice what it means in practice: the narrow ribbon is enforceable now, today, without waiting on an examiner. The wide ribbon is still argument. Scope is still moving in it. The company is still answering for it.
That skew is the honest shape of a young therapeutics file. Grants are slow and applications are cheap to keep alive. The interesting question is not the ratio but the ordering: the granted family traces back to that 2018 start, while the pending mass carries first filings from 2023, 2024 and two in 2025. The oldest bet is the one that landed.
The oldest bet is the one that has already cleared.
Peptides first, preparations second, nothing else
Two bands, and the larger is roughly twice the smaller. C07K, peptides and antibodies, takes the bulk of the claim weight. A61K, medicinal preparations, takes the rest. There is no third band worth drawing. For a company with five families and thirty-eight named inventors, that is an unusually disciplined footprint.
The recent published titles sit exactly where the bands say they should: cyclin inhibitors, and cyclative release of peptidic compounds. The most recent of those published on 23 April 2025. Nothing in the record wanders into adjacent chemistry, formulation platforms or delivery hardware. Whatever else the company does, the filings describe peptide chemistry and the preparations built from it.
Three names hold the whole file together
Thirty-eight inventors are named across five families. That is a wide field for so few filings, and most of those dots appear once. Then three are lit: Andrew T Bockus, on four of five. Breena F Walton, on four. Constantine Kreatsoulas, on four. The same three signatures recur from the early work through to the 2025 filings.
Read that as continuity rather than concentration. A file with thirty-eight contributors and no repeat names would suggest scattered projects stitched together after the fact. This one has a spine. The people who were present in 2018 are present in 2025, and the broad cast around them looks like collaborators drawn in per family rather than a shifting core.
Thirty-eight names, but only three appear on nearly everything.
A small circle in loud company
On the same scale, the other organisations filing in these CPC groups over the last five years are large. University of California at 106 families. Inst Nat Sante Rech Med at 99. Zhejiang University at 94. Regeneron Pharma at 81. Caregen at 61. Ocean Univ China at 59. Circle Pharma is the small dot, at five.
This is where count stops being the measure. In a space this densely filed, five families only matter if the claims are narrow enough to be defensible and specific enough to cover something real. The record offers one supporting signal: Zhejiang Baitai Biology, Anhui University, Genesis Therapeutics and Hangzhou Peptide Biochem have each cited these filings. Small files that get read are not the same as small files that get ignored.
What the next two filings decide
The story in this file is a five-year silence broken. One family in 2018, nothing until 2023, then one, one, and two in 2025. That is not a company that filed steadily and got funded for it. It is a company that filed once, went quiet, and started writing again two years before the money arrived.
The Series E does not change what has been claimed. It changes how much of the pending ribbon gets prosecuted to the end, and how fast. Five families is a position only if the four still open resolve with scope worth having. Everything the record says about intent is already written. What remains is whether it holds.
Is a small file a real position here?
Five families in a crowded claim space can mean discipline or thinness. No one of the three signals below settles it. Read them together, and weigh the granted family more heavily than the pending ones.
Five families and little else
Nothing granted, no inventor continuity, no outside citation. At that point the count is the whole story, and the count is small.
What the next two filings decide
Do the 2025 families keep the same three inventor names on them, or does the spine widen as headcount grows?
Does the second family reach grant, and does its allowed scope resemble the first?
Do new first filings continue to land only in C07K and A61K, or does a third band open?
Does the record expand beyond the two offices already used, US and EP?
Together those would tell you whether the Series E funded a broader programme or simply paid to finish the one already on file.
Common questions
How many patents does Circle Pharma have?
Circle Pharma holds 5 patent families as reviewed in 2026-09: 1 granted and 4 published and pending.
How many of Circle Pharma's patents are granted?
1 of the 5 families is granted, or 20 percent. The remaining 4 are published and still under examination.
What technology do Circle Pharma's patents cover?
Circle Pharma's claims cluster in peptides and antibodies (C07K) and medicinal preparations (A61K). Recent filing titles include "cyclin inhibitors" and "cyclative release of peptidic compounds".
Where has Circle Pharma filed patents?
Circle Pharma's families appear in 2 patent offices: United States and Europe.
Which companies file patents in the same areas as Circle Pharma?
The same CPC groups drew University of California, Inst Nat Sante Rech Med, Zhejiang University and Regeneron Pharma over the last five years. Shared classification indicates a common technology field rather than direct competition.
Who cites Circle Pharma's patents?
Patent records from Zhejiang Baitai Biology, Anhui University, Genesis Therapeutics and Hangzhou Peptide Biochem cite Circle Pharma's filings. A citation indicates a reference to the work, not evidence of commercial use.
Who invented Circle Pharma's patents?
38 inventors are named across the portfolio. The most frequently named is Andrew T Bockus. Inventor names do not establish ownership, which is determined by assignment records.
GET IN TOUCH NOW!
OR SCHEDULE A MEETING
